The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
May 17th 2025
Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.
Risk of Richter Transformation in CLL May Be Lower in Novel Agent Era
January 5th 2024An abstract presented at the 2023 American Society of Hematology Annual Meeting and Exposition suggests that patients with chronic lymphocytic leukemia (CLL) treated in the era of novel agents might be less likely to experience Richter transformation compared with those treated prior to this era.
Read More
What We’re Reading: Canadian Drug Imports; Drug-by-Mail Delivery; Hydroxychloroquine-Related Deaths
January 5th 2024The FDA announced it is allowing Florida to import medications in bulk from Canada at far lower prices than those offered in the United States; health insurance companies are revamping their technology to encourage more people to get their medications through the mail; nearly 17,000 patients with COVID-19 may have died after taking hydroxychloroquine during the first pandemic wave.
Read More
Dr Jonathan Silverberg Lists Which Patients With AD Benefit Most From JAK Inhibitors
January 4th 2024Jonathan Silverberg, MD, PhD, MPH, of George Washington University School of Medicine and Health Sciences, explains the benefits of using Janus kinase (JAK) inhibitors to treat patients with atopic dermatitis (AD).
Watch
What We’re Reading: Rising Hospital Care Costs; New Antibiotic; Disenrolled Medicaid Beneficiaries
January 4th 2024The average direct cost for hospital treatment for patients with COVID-19 in the United States rose by 26% from 2020 to 2022; scientists have developed a new type of antibiotic to treat a deadly bacteria resistant to most current antibiotics; a survey conducted for Utah state officials gave some clues as to why millions of Americans lost Medicaid coverage last year.
Read More
Experts explore the efficacy and safety profiles of elacestrant, an oral selective estrogen receptor degrader (SERD), and other options for endocrine therapy. The panelists also discuss clinical trial insights, progression-free survival rates, and tolerability, highlighting outcomes and advances in metastatic breast cancer treatment.
Watch
Dr Ian Neeland Describes Patient Experience During Semaglutide Shortage
January 3rd 2024Ian Neeland, MD, of University Hospitals Harrington Heart & Vascular Institute, describes challenges patients with diabetes face during the semaglutide shortage and alternative options he gives his patients to prevent therapy disruptions.
Watch
What We’re Reading: Drug Price Increases; FDA Approvals Rise; Abortion Pill Demand Surge
January 3rd 2024Drugmakers are expected to increase prices on more than 500 drugs early this month; the FDA approved nearly 50% more novel drugs in 2023 than in 2022; the number of Americans who were not pregnant and wanted abortion pills increased by nearly 10 times after the Supreme Court’s 2022 Roe v Wade decision leaked.
Read More
Proposed Guidance for DMD-Related Respiratory Function Evaluation in the UK
January 2nd 2024A multidisciplinary team has proposed respiratory care guidance for pediatric and adult patients living with Duchenne muscular dystrophy (DMD) in the United Kingdom (UK), with these recommendations meant to optimize DMD care day to day and in acute episodes.
Read More
Dr Elaine Siegfried Describes How AAD Guideline Update Impacts AD Treatment
January 1st 2024Elaine Siegfried, MD, of Saint Louis University School of Medicine, discusses how the recent guideline update by the American Academy of Dermatology (AAD) affects dermatologists' atopic dermatitis (AD) treatment decisions.
Watch
ICYMI: Highlights From EHA 2023
December 26th 2023The most-read articles from the 2023 European Hematology Association (EHA) Annual Meeting covered the most up-to-date treatment strategies for hematological malignancies, racial disparities in treatment patterns for blood cancers, and updates on immunotherapy as a tool in hematologic oncology.
Read More
Patients With Breast Cancer, HIV More Likely to Experience Suboptimal Adjuvant Chemotherapy Delivery
December 25th 2023The researchers noted the need for strategies to better support women living with HIV with breast cancer during toxic therapies to improve outcomes among this growing population.
Read More
ASH Abstracts Show PRO Improvements, Long-Term Efficacy of Cilta-Cel in MM
December 24th 2023Data presented at the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition highlighted improvements in patient-reported outcomes (PROs) with ciltacabtagene autoleucel (cilta-cel) in multiple myeloma (MM).
Read More
Most PCPs Unfamiliar With Biologic Therapy for Patients With Severe Asthma
December 24th 2023Two posters presented at the American College of Allergy, Asthma and Immunology 2023 Annual Scientific Meeting evaluated real-world biologic utilization for patients with severe, uncontrolled asthma.
Read More